Novimmune Completes CHF30 Million ($29.8 Million) Funding Round With Existing Shareholders

Broad Participation From Shareholder Base to Invest in Developing the Drug Pipeline, Including NI-0501 for Hemophagocytic Lymphohistiocytosis (HLH)

(firmenpresse) - GENEVA, SWITZERLAND -- (Marketwired) -- 01/11/16 -- Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related disorders and cancer, today announced it has completed a CHF30 million ($29.8 million) funding round.

"We are delighted to have completed a CHF30 million funding round driven by major commitments from our lead investors that secured broad participation from our existing shareholder base," said Novimmune Chairman and Chief Executive Officer Eduard Holdener. "This support from our shareholders demonstrates the confidence they have in the strength of our pipeline and in the future of the Company. We remain committed to further developing novel medicines to provide improved treatment options for patients suffering from rare and devastating diseases like Hemophagocytic Lymphohistiocytosis (HLH), as well as autoimmune and inflammatory diseases, and cancer."



Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva. More information is available on the company website at .



Eduard Holdener
+41 22 839 71 41

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 11.01.2016 - 14:00 Uhr
Sprache: Deutsch
News-ID 443338
Anzahl Zeichen: 1626

contact information:
Town:

GENEVA, SWITZERLAND

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 270 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Novimmune Completes CHF30 Million ($29.8 Million) Funding Round With Existing Shareholders"
steht unter der journalistisch-redaktionellen Verantwortung von

Novimmune SA (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for ...

GENEVA, SWITZERLAND -- (Marketwired) -- 03/16/16 -- Novimmune, a Swiss biotech company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to NI-0501 for the treatment of patients with primary ...

Change of Leadership at Novimmune S.A. ...

GENEVA, SWITZERLAND -- (Marketwired) -- 12/21/15 -- The Board of Directors at its meeting of December 16, 2015 appointed Ed Holdener as Chief Executive Officer of the Company, effective immediately.This decision comes following a series of significa ...

Novimmune Abstract Selected for the "Best of ASH" at the 2015 Annual M ...

GENEVA, SWITZERLAND -- (Marketwired) -- 12/15/15 -- Novimmune, a privately held, Swiss biotech company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory and rare diseases, immune-related diso ...

Alle Meldungen von Novimmune SA